PMAD Screening in Fertility Patients: When and How to Start

The Elevated Risk Profile

Patients pursuing fertility treatment represent a distinct clinical population for perinatal mental health risk. By the time they complete a successful cycle and enter the standard perinatal care pathway, many have experienced months to years of:

• Repeated treatment failures and pregnancy losses
• Hormonal interventions with direct psychiatric effects (GnRH agonists, high-dose estrogen and progesterone)
• Diagnostic uncertainty and information-seeking hypervigilance
• Relationship strain and financial stress

A 2021 prospective study in Human Reproduction (Chen et al.) found that IVF patients had significantly elevated rates of anxiety and depression compared to spontaneous conception patients at equivalent gestational ages. These differences persisted into the postpartum period even after successful delivery.

The standard perinatal care pathway -- first-trimester intake, third-trimester screen, postpartum visit -- was not designed with this population in mind. Fertility patients often arrive at obstetric care with pre-existing elevated psychological burden, prior loss history, and anticipatory anxiety that standard one-size-fits-all screening may miss.

---

When to Start Screening

At fertility treatment initiation

The most effective time to establish a baseline mental health assessment is before a cycle begins. This accomplishes two things: it identifies patients who are already distressed (and who would benefit from support during treatment), and it provides a pre-treatment baseline against which subsequent scores can be compared.

Recommended tool at initiation: PHQ-9 or GAD-7, or both. The EPDS is not yet indicated because there is no pregnancy. PHQ-9 + GAD-7 together provide depression and anxiety coverage in approximately 5 to 8 minutes and are straightforward to administer in a fertility intake context.

During active cycles

IVF patients in active stimulation cycles are under significant hormonal and emotional load. Post-retrieval and post-transfer are particularly high-risk periods: the wait for fertilization results, blastocyst reports, and implantation outcomes produces acute anxiety that frequently reaches clinical levels.

Brief check-ins using PHQ-4 (the ultra-brief 4-item combined depression/anxiety screen) are feasible in cycle monitoring appointments where time is limited. A PHQ-4 score of 3 or above on either subscale should prompt a full PHQ-9 or GAD-7 follow-up at the next available opportunity.

Following pregnancy loss or failed cycle

This is the highest-risk acute period in the fertility patient trajectory. Pregnancy loss at any gestational age carries elevated risk for major depression, acute grief response, and traumatic stress. Miscarriage following IVF -- where the investment was substantial and the loss expected to produce a live birth -- compounds this.

Repeat cycle patients with a failed cycle or pregnancy loss should receive a formal PHQ-9 and GAD-7 within 2 weeks of the loss, not at the standard follow-up appointment. Many fertility clinics do not have a systematic protocol for this. Without one, the patients most at risk are the ones who fall through.

At transition to obstetric care (positive beta HCG through first trimester)

The transition from fertility monitoring to standard OB care is logistically smooth for patients who are not psychologically fragile. For fertility patients -- particularly those with prior losses, those who achieved pregnancy after multiple failures, or those undergoing closely monitored high-risk pregnancy -- this transition can increase anxiety rather than relieve it.

Switch to the EPDS at this point. Administer at the first prenatal visit and again at 10 to 12 weeks. Flag elevated scores to the receiving OB so the care handoff includes mental health context.

---

Hormonal Factors in PMAD Risk for Fertility Patients

GnRH agonists and antagonists

Lupron (leuprolide acetate) and other GnRH agonists produce an estrogen-deficiency state that is frequently associated with mood effects including depressed mood, irritability, and sleep disruption. Patients undergoing down-regulation protocols may present with symptoms that overlap with MDD but are hormonally mediated.

Clinical implication: distinguish treatment-related hormonal symptoms from baseline depression when interpreting screening scores during active suppression. Elevated scores during Lupron suppression should be noted with context. A patient scoring 14 on the PHQ-9 during day 10 of Lupron suppression is in a different clinical situation than a patient scoring 14 three weeks post-retrieval with normal hormone levels.

Luteal phase support and progesterone

High-dose progesterone supplementation (commonly used in luteal phase support protocols) is associated with mood changes in a subset of patients, including depressive symptoms, irritability, and emotional lability. These symptoms typically resolve when progesterone is tapered in the second trimester.

Document timing relative to hormonal exposures when scoring during active treatment.

Postpartum hormone withdrawal

Fertility patients who achieve successful delivery may be at elevated risk for the postpartum hormone withdrawal that underlies postpartum depression. Some researchers have hypothesized that prolonged exogenous progesterone exposure during the first trimester followed by withdrawal may amplify the neuroendocrine changes associated with PPD, though evidence is limited. The clinical implication is heightened postpartum screening vigilance for this population regardless of prenatal emotional status.

---

Prior Pregnancy Loss and PTSD

Patients with prior pregnancy loss -- spontaneous abortion, recurrent pregnancy loss (RPL), or termination for medical reasons (TFMR) -- are at elevated risk for PTSD symptoms in subsequent pregnancies. This is distinct from depression and anxiety, and standard EPDS and GAD-7 screening may not capture it adequately.

The Perinatal Posttraumatic Stress Questionnaire (PPQ) or City Birth Trauma Scale can be used adjunctively for patients with known prior loss. The PPQ has been validated for perinatal populations and captures hypervigilance, avoidance, and intrusion symptoms that are specific to pregnancy-related trauma.

At minimum, direct clinical inquiry is appropriate for any patient with prior pregnancy loss: "Some patients who have been through a pregnancy loss find that subsequent pregnancies bring up a lot of anxiety or difficult memories. Has that been your experience?"

---

Communicating About Mental Health in the Fertility Context

Fertility patients are often highly educated, medically sophisticated, and accustomed to aggressive monitoring of physical parameters. They may be less receptive to mental health screening framing that feels separate from their medical care.

Effective framing:

"We pay very close attention to your hormones, your follicle development, and your embryo quality. The research also tells us that your emotional state during treatment affects outcomes -- stress hormones affect implantation, sleep affects cycle response -- so we take mental health monitoring seriously as part of your protocol."

This frames mental health screening as medically integrated rather than a separate concern, which is both clinically accurate and consistent with how this patient population processes information.

---

Building Screening Into the Fertility Clinic Workflow

Most fertility clinics do not have formalized PMAD screening workflows. The following is a practical implementation framework:

Step 1: Add PHQ-9 and GAD-7 to the initial fertility consultation intake paperwork. Score at baseline.

Step 2: Add PHQ-4 to monitoring appointment check-in for patients in active cycles. Flag scores 3 or above to the care coordinator or nurse.

Step 3: Establish a post-loss protocol: PHQ-9 and GAD-7 within 14 days of any pregnancy loss or failed cycle, administered by the nurse or care coordinator.

Step 4: At the transition-to-OB appointment, administer the EPDS and send the score and clinical summary to the receiving OB as part of the care handoff.

Step 5: Identify a perinatal mental health referral resource with experience treating fertility patients and pregnancy loss. Brief the clinical staff on what that referral looks like.

---

Referral Considerations

Fertility patients referred for perinatal mental health care benefit most from providers with:

• Experience with pregnancy loss grief and RPL trauma
• Familiarity with the psychological landscape of fertility treatment
• Knowledge of evidence-based treatments for perinatal anxiety and PTSD (CBT, ERP for OCD, trauma-focused therapies)
• Willingness to coordinate with the fertility team on treatment-related mood effects

The PMH-C (Perinatal Mental Health Certification) credential indicates advanced training in perinatal mental health including pregnancy loss, fertility, and postpartum disorders. Most general therapists do not have this background.

For an overview of referral pathways and what patients experience after a fertility-to-mental-health handoff, see our article on care coordination and warm handoffs in perinatal mental health.